Trial Profile
An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Jun 2018
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Spinocerebellar ataxias
- Focus Therapeutic Use
- 26 May 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 14 Nov 2014 New trial record